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Abstract
Background: Although acute otitis media (AOM) remains a major public health problem worldwide and brings
economic burden on health care system and caregivers, little information is available about its epidemiology in
Eastern Europe.
Methods: We conducted an epidemiological, prospective, observational, multi-centre cohort study (NCT01365390)
in five East European countries (Estonia, Lithuania, Poland, Romania and Slovenia) between June 2011 and January
2013 to determine the incidence and clinical characteristics of AOM among children aged < 6 years during 1 year.
Results: AOM incidence was 160.7 cases (95 % confidence interval [CI]: 144.7–177.9) per 1000 person-years (PY) being
the lowest in the < 1 year age group (92.3 cases [95 % CI: 59.7–136.2] per 1000 PY) and the highest in the 3– < 4 years
age group (208.9 cases [95 % CI: 165.1–260.7] per 1000 PY). AOM incidence was similar across the countries, with the
exception of Slovenia (340.3 cases [95 % CI: 278.3–412.0] per 1000 PY). There was a lower risk in breastfed children and
a higher risk in those attending school/childcare or with allergies. AOM required 521 visits to the doctor. Antibiotics
were prescribed for 276 (74.8 %) episodes with the lowest prescription rate in Estonia (51.4 %) and the highest in
Romania (83.7 %). Complications were rare and hospitalisations occurred in 2 % of the cases.
Conclusions: The disease burden of AOM in Eastern Europe is relevant and public health initiatives to reduce it should
be considered.
Trial registration: ClinicalTrial.gov NCT01365390.
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Background
Acute otitis media (AOM) remains a major public health
problem worldwide with 80 % of children experiencing
an episode before the age of 3 years [1]. AOM may have
non-specific symptoms, have frequent recurrences, often
require several visits to the health care practitioner and
is a primary reason for antibiotic prescription in children
[2, 3]. All of this brings challenges and economic burden
to the everyday health care system [4, 5]. In addition to
this, AOM brings emotional and economic burden to
the caregivers and may have a negative impact on their
quality of life [6].
Little information is available about specific epidemi-
ology of AOM in Eastern Europe. One publication from
Poland reported that at least 65 % of children suffer from
AOM by the age of 2 years [7]. In Romania, the microbiol-
ogy and antibiotic susceptibility was described but no data
on incidence or clinical practice exists till date [8]. We
therefore undertook this study to estimate the incidence
and describe demographic and clinical characteristics of
AOM in children less than 6 years of age visiting Primary
Care Paediatricians in five East European countries
(Estonia, Lithuania, Poland, Romania and Slovenia).* Correspondence: vytautas.usonis@mf.vu.lt
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Methods
This prospective, observational, multi-centre cohort
study (NCT01365390) was conducted at 29 primary
healthcare clinics in five East European countries
(Estonia = 1, Lithuania = 3, Poland = 10, Romania = 5 and
Slovenia = 10) between 10 June 2011 and 20 January
2013. In addition, retrospective data from the previous
year or from birth for children younger than 1 year of
age at enrolment was collected for all children.
Children were selected from the paediatric population
registered at the participating practices and parents were
contacted via mail, telephone or during a routine visit.
Children with an AOM episode and/or upper respiratory
tract infection at the time of enrolment were excluded
from participating in the study; children with no
available medical history from the previous year or from
birth if less than 1 year of age at enrolment were also ex-
cluded. Written informed consent was obtained from
parents of all participating children before any study
procedure was performed.
Of the 377,750 children who were registered in the
practices, 2258 were enrolled in our study. One was
excluded due to protocol violation and 2253 were valid
for the follow-up analysis.
Demographics as well as information on pneumococcal
vaccination history, method of feeding, day-care/school at-
tendance, number of household siblings, prematurity, aller-
gies, and exposure to indoor cigarette smoke were collected
(Table 1). Medical records of the enrolled children were
reviewed to retrieve information on physician-diagnosed
Table 1 Demographic characteristics of enrolled children
Medical record reviewa
Characteristics Estonia Lithuania Poland Romania Slovenia Total
N 250 300 1106 301 300 2257
Age (months) Median (range) 36 (3–71) 27.5 (0–71) 24 (0–71) 34 (2–71) 27 (1–70) 28 (0–71)
Gender, n (%) Female 122 (48.8) 154 (51.3) 554 (50.1) 139 (46.2) 157 (52.3) 1126 (49.9)
Male 128 (51.2) 146 (48.7) 552 (49.9) 162 (53.8) 143 (47.7) 1131 (50.1)
Pneumococcal vaccination (at least 1 dose), n (%) Yes 21 (8.4) 35 (11.7) 513 (46.4) 47 (15.6) 45 (15.0) 661 (29.3)
No 227 (90.8) 265 (88.3) 590 (53.3) 254 (84.4) 255 (85.0) 1591 (70.5)
Unknown 2 (0.8) 0 (−) 3 (0.3) 0 (−) 0 (−) 5 (0.2)
Child feeding, n (%) Breast-fed 14 (5.6) 62 (20.7) 193 (17.5) 26 (8.6) 32 (10.7) 327 (14.5)
Formula-fed 2 (0.8) 32 (10.7) 164 (14.8) 39 (13.0) 25 (8.3) 262 (11.6)
Regular food 243 (97.2) 245 (81.7) 837 (75.7) 259 (86.0) 269 (89.7) 1853 (82.1)
Child care/school attendance, n (%) 2–5 children 25 (10.0) 1 (0.3) 32 (2.9) 100 (33.2) 12 (4.0) 170 (7.5)
6–10 children 13 (5.2) 1 (0.3) 9 (0.8) 15 (5.0) 6 (2.0) 44 (1.9)
> 10 children 175 (70.0) 145 (48.3) 350 (31.6) 144 (47.8) 185 (61.7) 999 (44.3)
Follow-up periodb
Characteristics Estonia Lithuania Poland Romania Slovenia Total
N 249 299 1104 301 300 2253
Age (months) Median (range) 36 (3–71) 28 (0–71) 24 (0–71) 34 (2–71) 27 (1–70) 28 (0–71)
Gender, n (%) Female 121 (48.6) 153 (51.2) 553 (50.1) 139 (46.2) 157 (52.3) 1123 (49.8)
Male 128 (51.4) 146 (48.8) 551 (49.9) 162 (53.8) 143 (47.7) 1130 (50.2)
Nc 249 298 1100 300 298 2245
Pneumococcal vaccination (at least 1 dose), n (%)d Yes 14 (5.6) 15 (5.0) 200 (18.2) 15 (5.0) 11 (3.7) 255 (11.4)
No 235 (94.4) 283 (95.0) 884 (80.4) 285 (95.0) 287 (96.3) 1974 (87.9)
Unknown 0 (−) 0 (−) 16 (1.5) 0 (−) 0 (−) 16 (0.7)
N total number of subjects
n (%) number (percentage) of subjects in each group
aOnly 1 subject from Poland was excluded from the According-To-Protocol (ATP) cohort for retrospective analysis for protocol violation
b5 subjects (1 subject from Poland for protocol violation and 1 subject each from Estonia and Lithuania and 2 subjects from Poland for lost to follow-up) were
excluded from the ATP cohort for prospective analysis
cNumber of subjects available at study conclusion
dSum of percentages may exceed 100 % due to rounding
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AOM episodes during the year before enrolment or since
birth for children younger than 1 year of age.
Parents were instructed to visit the doctor each time the
child had symptoms of AOM and/or upper respiratory
tract infection within 12 months after enrolment. AOM
was diagnosed by the investigator based on clinical
judgement. Detailed information on the signs, symptoms,
severity [using the Otoscopic Severity (OS)-8 scale for
assessment of tympanic membrane and AOM Faces scale
for the evaluation of severity of AOM symptoms] [9],
course and treatment were recorded. No samples were
collected as part of this study.
After 14–21 days of the first visit to an investigator for
a new episode of AOM, the parents/guardians were
contacted by telephone to collect information on the
evolution and management of the episode.
Additionally, parents were contacted every 2 months
to report any AOM symptoms and/or respiratory tract
infection lasting ≥ 48 h, experienced by their child in the
previous 2 months if not reported to the investigator.
They were also required to report all visits made to
other health care professionals (including all hospitalisa-
tions, emergency room visits, etc.) for any AOM or
respiratory tract infection lasting ≥ 48 h.
Standard practices and recommendations in each
country were followed for treatment and follow-up of
each episode of AOM until resolution.
The study adhered to the Good Clinical Practice
guidelines, including the Declaration of Helsinki and
was conducted according to applicable regulatory re-
quirements. The study was reviewed and approved by a
national, regional, or investigational centre Independent
Ethics Committee/Institutional Review Board.
The target sample size was 2200 children for an ex-
pected incidence of AOM of 26.8 cases per 100 person-
years (PY) [10] (95 % Exact Poisson confidence interval
(CI) [24.70–29.01]). The overall incidence of AOM
episodes and the incidence by country were estimated
with 95 % CI. The incidence of AOM was expressed as
number of AOM cases per 1000 PY. The severity of
AOM was described in terms of frequency of signs and
symptoms, hospitalisations and complications. Crude
and adjusted odds ratios (OR) and their 95 % CI were
calculated using logistic regression analysis. The statis-
tical analyses were performed using the Statistical Ana-
lysis System (SAS-version 9.2) Drug and Development
(SDD) web portal version 3.5 and Microsoft Excel 2007.
Results
The median age of the 2258 enrolled children was
28 months (range: 0–71 months), and 50.2 % (1130) were
male; 14.5 % (327) of children were breast-fed and 53.7 %
(1213) of children attended day-care service (Table 1).
At least one dose of pneumococcal conjugate vaccine
(PCV) had been administered to 661 (29.3 %) children
prior to enrolment, the lowest being in Estonia (21; 8.4 %)
and the highest in Poland (513; 46.4 %) (Table 1). In
addition, at least one dose of PCV was administered to 14
(5.6 %) children in Estonia, and 15 (5.0 %) each in
Lithuania and Romania during the study follow-up period.
The overall incidence of physician-diagnosed AOM
during the 1 year follow-up period was 160.7 cases
(95 % CI: 144.7–177.9) per 1000 PY. The incidence was
the lowest in Poland (115.7 [95 % CI: 96.7–137.3] cases
per 1000 PY) and highest in Slovenia (340.3 [95 % CI:
278.3–412.0] cases per 1000 PY) (Table 2).
The incidence of AOM was the lowest in the < 1 year
age group (92.3 cases [95 % CI: 59.7–136.2] per 1000
PY) and the highest in the 3– < 4 years age group (208.9
cases [95 % CI: 165.1–260.7] per 1000 PY).
No difference was found when comparing vaccinated and
non-vaccinated children: the incidence of AOM was 146.6
(95 % CI: 103.7–201.2) per 1000 PY in children who re-
ceived at least one dose of PCV and 163.3 (95 % CI: 146.1–
181.9) per 1000 PY in children who did not receive PCV.
A total of 246 (10.9 %) children experienced one AOM
episode, 42 (1.9 %) two episodes and 12 (0.5 %) three or
more during the follow-up study period (Fig. 1). Overall,
Table 2 Incidence of AOM episodes as diagnosed by a primary care physician or an otolaryngology specialist
Medical record review Follow-up period
Total number of AOM
episodes (total population)
Incidence per 1000
person-years (95 % CI)
Total number of AOM
episodes (total population)
Incidence per 1000
person-years (95 % CI)a
Estonia 24 (250) 97.7 (62.6–145.3) 35 (249) 137.8 (96.0–191.7)
Lithuania 58 (300) 225.2 (171.0–291.2) 55 (299) 184.0 (138.6–239.6)
Poland 121 (1106) 130.5 (108.3–155.9) 131 (1104) 115.7 (96.7–137.3)
Romania 34 (301) 118.7 (82.2–165.9) 43 (301) 141.9 (102.7–191.1)
Slovenia 125 (300) 455.3 (379.0–542.5) 105 (300) 340.3 (278.3–412.0)
Overall total 362 (2257) 181.8 (163.5–201.5) 369 (2253) 160.7 (144.7–177.9)
There is no overlap of dates between “Medical record review” and “Follow-up” period. The subjects were followed-up from June 2011 to January 2013
The medical records were reviewed 12 months prior to enrolment (entire birth period for subjects aged below 1 year)
AOM acute otitis media, CI confidence interval
aBased on the actual surveillance period since some subjects were followed-up for more than 1 year
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96 (26.0 %) of these episodes (Estonia: 1 [0.3 %];
Lithuania: 44 [11.9 %]; Poland: 16 [4.3 %]; Romania: 8
[2.2 %]; Slovenia: 27 [7.3 %]) required more than one
visit to the doctor. The most frequently reported symp-
toms were ear pain/otalgia (271; 75.1 %) followed by
fever (208; 57.6 %) (Table 3). Seven complications oc-
curred after 369 AOM episodes (Table 3).
Ten episodes (2.7 %) were referred to the hospital, of
which 80.0 % required subsequent hospitalisation and
most cases (77; 23.1 %) were of a severity rating of 4 on
the AOM Faces Scale (Table 3).
Antibiotics have been prescribed for at least 276
(74.8 %) episodes in all countries with the lowest
prescription rate of 51.4 % in Estonia and the highest
rate of 83.7 % in Romania. Parents took days off work
due to episodes of AOM in their children in 22.7 %
of the cases with some country variation between 4.7
to 31.3 %.
When looking at the year before enrolment into the
study, it was found that a total of 212 (9.4 %) children
experienced one AOM episode, 46 (2.0 %) two episodes,
18 (0.8 %) three or more (Fig. 1). Overall, 78 (21.5 %) of
these episodes (Estonia: 1 [0.3 %]; Lithuania: 40 [11.0 %];
Poland: 13 [3.6 %]; Romania: 1 [0.3 %]; Slovenia: 23
[6.4 %]) required more than one visit to the doctor due
to AOM. Complications were recorded for three AOM
episodes. Antibiotics were prescribed for at least 298
(82.5 %) AOM episodes in all countries with the lowest
prescription rate of 73.5 % in Romania and the highest
rate of 92.8 % in Slovenia. AOM episodes led to hospital
referrals in 5.3 % cases, of which 89.5 % required subse-
quent hospitalisation. Tympanocentesis was performed
for one episode (1.9 %).
Protective effect of breast-feeding against AOM has
been revealed in univariate analysis (adjusted OR:
0.19; 95 % CI: 0.08−0.44). On the contrary, increased
risk of AOM was found in the children attending
child care or school (especially with higher number of
children per child care) (adjusted OR: 1.92; 95 % CI:
1.35–2.75) and for those with allergies (adjusted OR:
1.64; 95 % CI: 1.09–2.45) (Table 4). There was no sig-
nificant association between AOM and other risk
factors such as age, gender, pneumococcal vaccin-
ation, presence of household siblings, exposure to
smoking, and premature birth.
Discussion
This study was conducted to determine the incidence
of AOM in children less than 6 years of age in
Estonia, Lithuania, Poland, Romania and Slovenia. We
observed that a minimal variation in AOM incidence
exists across the five East European countries.
Although the incidence of AOM in this study (160.7
cases (95 % CI: 144.7–177.9) per 1000 PY) was lower
than what was previously reported in a similar study
conducted in Western Europe (256 cases [95 % CI:
243–270] per 1000 PY) [10], our findings emphasise
the health burden due to AOM in children below
6 years of age in five East European countries
(Estonia, Lithuania, Poland, Romania and Slovenia).
Indeed, the incidence of AOM in our study is also lower
compared to what was reported in Finland (32 cases [95 %
CI: 30–34] per 100 PY) [11], appears to be higher
compared to that in the Czech Republic (83.3–125.2 cases
per 1000 PY) [12] and similar to the incidence in Italy
(168 cases [95 % CI: 167–169] per 1000 PY) [13]. This
could be due to several factors such as seeking behaviour
(a)
(b)
Fig. 1 Percentage of subjects with 1, 2, 3, or 4 or more acute otitis
media episodes as diagnosed by a physician or an otolaryngology
specialist, by country during the retrospective (a) and prospective
(b) parts of the study
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for treatment of AOM, diagnostic procedures [14, 15], so-
cioeconomic status of the parents, climate and genetic
predisposition [16].
Children in this study had on average 1.23 episodes, and
each episode required 1.41 visits to the doctor. The
number of the visits varied by country which could be due
to specificity of health care practice in each country.
Antibiotic prescription for AOM in East European
countries is confirmed to be relatively high with the
exception of Estonia where this rate is lower and
accounted for only 50 %. This could be due to well applied
strategies on watch and see for the AOM symptoms.
Based on country experience in Lithuania, AOM is an
important reason for antibiotic prescription, but practices
Table 3 Clinical and health economic characteristics of AOM episodes during the follow-up period
Characteristics Estonia Lithuania Poland Romania Slovenia Total
Clinical signs/symptoms
Na 34 52 131 43 101 361
Ear Pain/Otalgia, n (%) 30 (88.2) 40 (76.9) 101 (77.1) 33 (76.7) 67 (66.3) 271 (75.1)
Ear discharge, n (%) 4 (11.8) 2 (3.9) 4 (3.1) 1 (2.3) 7 (6.9) 18 (5.0)
Hearing loss, n (%) 11 (32.4) 6 (11.5) 3 (2.3) 0 (−) 4 (4.0) 24 (6.7)
Ear tugging, n (%) 5 (14.7) 1 (1.9) 4 (3.1) 26 (60.5) 15 (14.9) 51 (14.1)
Perforation of tympanic membrane, n (%) 1 (2.9) 0 (−) 2 (1.5) 0 (−) 5 (5.0) 8 (2.2)
Fever, n (%) 11 (32.3) 19 (36.5) 77 (58.8) 38 (88.4) 63 (62.4) 208 (57.6)
Hospitalisation and complications
N 35 55 131 43 105 369
Child referred to hospital due to AOM, n (%) 0 (−) 2 (3.6) 7 (5.3) 0 (−) 1 (1.0) 10 (2.7)
Was the child hospitalised, n (% of those referred) - 1 (50.0) 6 (85.7) - 1 (100.0) 8 (80.0)
Complications, n (%) 3 (8.6) 0 (−) 3 (2.3) 1 (2.3) 0 (−) 7 (1.9)
Procedures performedb
N 1 0 36 0 3 40
Adenoidectomy 0 (−) 0 (−) 1 (2.8) 0 (−) 0 (−) 1 (2.5)
Ventilation tube insertion 1 (100.0) 0 (−) 0 (−) 0 (−) 0 (−) 1 (2.5)
Cleaning of tube 0 (−) 0 (−) 36 (100.0) 0 (−) 3 (100.0) 39 (97.5)
Severity scorec
N 35 55 131 43 105 369
1, n (%) 5 (14.3) 2 (3.6) 4 (4.0) 1 (2.4) 5 (5.0) 17 (5.1)
2, n (%) 10 (28.6) 3 (5.5) 28 (27.7) 0 (−) 11 (10.9) 52 (15.6)
3, n (%) 5 (14.3) 10 (18.2) 34 (33.7) 5 (12.2) 11 (10.9) 65 (19.5)
4, n (%) 0 (−) 10 (18.2) 17 (16.8) 23 (56.1) 27 (26.7) 77 (23.1)
5, n (%) 5 (14.3) 11 (20.0) 10 (9.9) 9 (22.0) 24 (23.8) 59 (17.7)
6, n (%) 5 (14.3) 13 (23.6) 6 (5.9) 2 (4.9) 20 (19.8) 46 (13.8)
7, n (%) 5 (14.3) 6 (10.9) 2 (2.0) 1 (2.4) 3 (3.0) 17 (5.1)
Missing confirmed, n (%) 0 (−) 0 (−) 30 (−) 2 (−) 4 (−) 36 (−)
Caregiver missed workc
Nd 16 54 121 43 101 335
Yes 5 (31.3) 11 (20.4) 30 (24.8) 2 (4.7) 28 (27.7) 76 (22.7)
No 11 (68.8) 43 (79.6) 91 (75.2) 41 (95.3) 73 (72.3) 259 (77.3)
AOM acute otitis media
N total number of AOM episodes
n (%) number (percentage) of AOM episodes in each group
aTotal number of AOM episodes for which signs/symptoms were recorded during at least one of the visit
bSum of percentages may exceed 100 %, since more than one procedure had been performed
cSum of percentages may exceed 100 % due to rounding
dTotal number of AOM episodes for which health economics questionnaire was available
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could differ between countries. There also might be a ten-
dency to access secondary care first which is an added rea-
son for under-reported incidence of diseases like AOM.
At the time of this study, none of the participating coun-
tries had included PCV into their routine vaccination
program.
The major symptom of AOM was ear pain/otalgia
followed by ear discharge and hearing loss which was
consistent with previous results [17].
As expected, breast feeding has a protective effect
against AOM occurrence. This finding is in line with pre-
viously published studies [18–20]. In a review and meta-
analysis article, it was observed that the infants fed with
any formula during the first 6 months of life had twice the
odds of developing AOM as breastfed children (OR: 2.00;
95 % CI: 1.40–2.78) [19]. In another study, it was seen that
the percentage of children with AOM was lower among
breast fed compared to formula fed; 2 % vs. 16 % in
children aged 2 months (p = 0.01) and 13 % vs. 62 % in
children aged 6 months (p = 0.0001) [20]. Therefore, as
the World Health Organization recommends, breast
feeding should occur at least for the first 6 months of
infancy [21]. We also found an increased risk of AOM for
children with allergies, as observed in another study [22].
The higher incidence of AOM in child attending care
centres can be explained by the higher transmission rate
observed there [23].
Parents required staying home and missing work
due to AOM episode affecting their child in about
23 % of the cases, which can be due to the fact that
very often other relatives, especially retired grandpar-
ents, help with this.
Strengths of our study include the close follow-up of
the study children that made it possible to detect AOM
episodes even if the parents failed to communicate
proactively the suspicion of a positive case. This could
have also led to a limitation if parents gave the children
medication for a fever prior to the AOM visit, resulting
in under-reporting of the level of fever. All five countries
in the study used the same standardised protocol thus
facilitating country-wise comparisons. One limitation of
this study is the case definition for AOM: clinical
judgement made by general practitioners might have not
been accurate, but primary care setting is a better proxy
to general population epidemiology. If specialised clinics
were to be included, the better accuracy of diagnosis
would have been accompanied with a low representa-
tiveness of the studied population. Furthermore, the
burden of AOM can be valuably assessed based on the
prevalence of doubtful cases, without relying exclusively
on the diagnosis of otolaryngology specialist [10].
Another limitation of the study is that no information
were collected about those children not willing to par-
ticipate or whose contact was not possible, so that we
cannot ensure that they might not be different from
those enrolled. Finally, there might be differences in case
definitions of AOM between the countries under study.
Conclusions
We conclude that the disease burden of AOM in Eastern
Europe is relevant and consistent between the five
countries. Public health initiatives, such as prevention
through vaccination, should be considered to reduce the
disease burden of AOM on the society and public health
sector.
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